Recommendation of the President – Ozempic (semaglutide)
On 21 May 2026, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 70/2026 on the inclusion of the medicinal product Ozempic (semaglutide) in the reimbursement program for the following indication: type 2 diabetes in patients treated with at least one hypoglycemic agent, with HbA1c ≥ 7.0%, a BMI ≥ 27 kg/m², and very high cardiovascular risk, defined as: 1) confirmed cardiovascular , or 2) damage to other organs manifested by: proteinuria or left ventricular hypertrophy or retinopathy, or 3) the presence of 2 or more major risk factors from among those listed below: age ≥ 55 years for men, ≥ 60 years for women; dyslipidemia; hypertension; smoking
